Industry & Policy News

[The Guardian] Published in the journal Nature Communications, a study involved 25 patients with long COVID who reported experiencing malaise after exercising, and 21 people who had had COVID but made a full recovery. None of the participants had been hospitalised with Covid, while all had been fit and healthy before catching the virus and were of working age.

[University of Victoria] The University of Victoria celebrates the achievements of their exceptions researchers whose dedication shapes academia and societal progress, including Nicole York, whose studying the role of the ankyrin-B protein’s in cardiomyocyte development.

[Eli Lilly] Lilly Stands Against the Use of its Medicines for Cosmetic Weight Loss: Mounjaro and Zepbound are indicated for the treatment of serious diseases; they are not approved for – and should not be used for – cosmetic weight loss.

[Los Angeles Business Journal] It was announced that researchers at UCLA Health Jonsson Comprehensive Cancer Center received two grants totaling $9.1 million from the National Cancer Institute to advance liquid biopsy technologies for the early detection of cancer.

[Merck] Merck announced the initiation of pivotal Phase III trials for four of its investigational candidates from its diverse pipeline in hematologic malignancies and solid tumors.

[Science] A new and potentially controversial method, growing tiny, brainlike structures called organoids in a dish from human fetal brain tissue, could provide a realistic model and improve the study of developmental disorders or brain cancers.